## **Kluwer Patent Blog**

## Merck vs. Ratiopharm, Court of Appeal Helsinki (Helsingin Hovioikeus), 31 December 2010

Johanna Lilja (Roschier) · Monday, February 25th, 2013

The Helsinki Court of Appeal found that ratiopharm had infringed Merck's supplementary protection certificate covering losartan. The Court applied the reversed burden of proof of the Patents Act, which has its basis on Article 34 of the TRIPS Agreement. It further considered that, in the absence of proof to the contrary, the active ingredient losartan in ratiopharm's Losatrix- and Losatrix Comp -products was deemed to have been produced using a manufacturing process within the scope of Merck's patent.

A summary of this case will be posted on http://www.Kluweriplaw.com

## **Kluwer IP Law**

The **2022 Future Ready Lawyer survey** showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?


Learn how Kluwer IP Law can support you.

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe here.

79% of the lawyers think that the importance of legal technology will increase for next year.

**Drive change with Kluwer IP Law.** The master resource for Intellectual Property rights and registration.





2022 SURVEY REPORT The Wolters Kluwer Future Ready Lawyer Leading change

This entry was posted on Monday, February 25th, 2013 at 4:50 pm and is filed under (Indirect) infringement, Case Law, Chemical Engineering, Finland

You can follow any responses to this entry through the Comments (RSS) feed. Both comments and pings are currently closed.